FCGR3B Copy Number Loss Ups SLE, Lupus Nephritis Risk

This article originally appeared here.
Share this content:
<i>FCGR3B</i> Copy Number Loss Ups SLE, Lupus Nephritis Risk
FCGR3B Copy Number Loss Ups SLE, Lupus Nephritis Risk

THURSDAY, June 11, 2015 (HealthDay News) -- Fc gamma receptor 3B (FCGR3B) copy number (CN) loss is associated with increased risk of systemic lupus erythematosus (SLE) and lupus nephritis (LN), according to a meta-analysis published in the May issue of the International Journal of Rheumatic Diseases.

Jin Yuan, from Huashan Hospital affiliated to Fudan University in Shanghai, and colleagues conducted a systematic literature review and meta-analysis to examine the role of FCGR3B CN in the susceptibility of SLE and LN. Six articles were included in the study, with five comparisons of SLE between 2,490 patients and 4,286 controls and four comparisons of LN between 689 patients and 1,924 controls.

The researchers found that, compared with the normal genotype, individuals with FCGR3B CN gain did not have increased risk of SLE (odds ratio [OR], 1.07; 95 percent confidence interval [CI], 0.79 to 1.45; P = 0.65) or LN (OR, 0.83; 95 percent CI, 0.47 to 1.46; P = 0.52). The risks of SLE and LN were increased for individuals with FCGR3B CN loss (SLE OR, 1.77; 95 percent CI, 1.51 to 2.06; P < 0.00001; LN OR, 2.02; 95 percent CI, 1.59 to 2.57; P < 0.00001).

"In conclusion, our meta-analysis confirmed that low FCGR3B CN was related to the increased risk for both SLE and LN," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »